ADCT LOTIS-7 Full Data: $134M Market Cap, 89.8% ORR

ADC Therapeutics closed Friday at $1.05, valuing the company at $133.6 million. That’s less than two years of ZYNLONTA revenue for a company with an FDA-approved drug, $231 million in cash, and data from two clinical trials that would justify a billion-dollar valuation at a different biotech. The market has not missed this. It has simply decided ADCT is not worth more.

The market is mostly right, but the LOTIS-7 full data in Q4 2026 is the one catalyst that could change the story. Here’s the math on why the stock is where it is, and what the data needs to show.

LOTIS-5: The Confirmatory Trial Delivered, but Quietly

On June 3, ADC Therapeutics announced topline results from LOTIS-5 (NCT04384484), the Phase 3 confirmatory trial of ZYNLONTA plus rituximab versus R-GemOx in relapsed or refractory DLBCL. The study met its primary endpoint of progression-free survival with a hazard ratio of 0.73 (p=0.008), with median PFS of 6.1 months versus 4.7 months for R-GemOx.

The complete response rate favored ZYNLONTA at 39.5% versus 26.7%, and patients on ZYNLONTA had longer duration of response. On efficacy, the trial did what it needed to do: ZYNLONTA plus rituximab beat the standard salvage chemotherapy in a randomized Phase 3.

The problem was safety. Grade 5 treatment-emergent adverse events occurred in 13.2% of patients on ZYNLONTA plus rituximab versus 4.6% on R-GemOx. That’s a 2.9x higher rate of fatal adverse events in a trial where the efficacy benefit was a 1.4-month PFS improvement. The toxicity signal is what kept ADCT from rallying on the data. The stock was already below $2 before the readout and did not recover.

ADC Therapeutics said it would discuss next steps with the FDA for the ZYNLONTA-rituximab combination. That’s regulatory language for “we need to figure out if the benefit-risk profile supports a filing.” A 1.4-month PFS improvement against a 13.2% Grade 5 TEAE rate is not a launch vehicle.

LOTIS-7: The Real Catalyst

LOTIS-7 is the combination that matters. The Phase 1b trial evaluates ZYNLONTA plus glofitamab, Roche’s CD20xCD3 bispecific antibody, in relapsed or refractory DLBCL. Enrollment completed June 30 with 100 patients at the selected 150 µg/kg dose of ZYNLONTA.

The earlier data cut, reported in December 2025, showed an 89.8% overall response rate and 77.6% complete response rate across 49 efficacy-evaluable patients with a minimum of six months of follow-up. Those are CAR-T-like numbers from an off-the-shelf combination. For context, CAR-T therapies in 3L+ DLBCL report ORRs of 52 to 83% and CR rates of 40 to 58% in their registrational Phase 3 trials. ZYNLONTA plus glofitamab at 89.8% ORR and 77.6% CR outperforms every approved CAR-T on cross-trial comparison.

The catch is durability. CAR-T delivers durable remissions. Bispecific antibody combinations, including this one, have not yet shown whether responses last. The full LOTIS-7 data expected in Q4 2026 will answer the durability question: what is the median duration of response, and how many patients remain in CR at 12 and 18 months?

The Competitive Reality: DLBCL Is Not a Single-Drug Market

The DLBCL treatment algorithm has transformed over the past five years. Frontline R-CHOP or POLA-R-CHP cures roughly 60% of patients. For the 40% who relapse, second-line CAR-T with Yescarta or Breyanzi is now standard of care after ZUMA-7 and TRANSFORM showed superior event-free survival over salvage chemotherapy plus autologous transplant.

The third-line-plus setting is where ZYNLONTA currently competes, and it is crowded. Epcoritamab (AbbVie/Genmab) and glofitamab (Roche) are both approved as monotherapy for 3L+ DLBCL with ORRs of 52 to 63% and CR rates of 32 to 39%. ZYNLONTA monotherapy in 3L+ has an ORR of 48% and CR of 24%. It is the fourth or fifth option in a setting where CAR-T and bispecifics already set a higher bar.

The ZYNLONTA-plus-glofitamab combination in LOTIS-7 changes the math. If the durability data holds, an 89.8% ORR and 77.6% CR combination moves ZYNLONTA from the back of the 3L+ line to the front of the 2L+ line, ahead of CAR-T for patients who cannot tolerate or access cell therapy. Bispecific combinations avoid the manufacturing delay, bridging chemotherapy, and CRS risk of CAR-T. An off-the-shelf combination with CAR-T-like efficacy is a product that commercial payers will cover.

Valuation: What $134 Million Buys

ADC Therapeutics generated $20.0 million in Q1 2026 ZYNLONTA net product revenue, up 15% year over year. Full-year 2025 revenue was $73.6 million. The company had $231.0 million in cash as of March 31, 2026, against a quarterly operating loss of approximately $33 million. At the current burn rate, cash extends into early 2028, beyond the LOTIS-7 full data readout.

The market cap of $133.6 million values the company at roughly 1.8x annualized revenue. That’s a value-trap multiple for a reason: the approved 3L+ indication is small, the LOTIS-5 safety signal limits the rituximab combination’s commercial path, and the LOTIS-7 glofitamab combination, while clinically promising, has no defined regulatory path until the full data is published.

For comparison, ADCs as a class trade at wide multiples when they have a clear label-expansion story. Daiichi Sankyo built a franchise on ENHERTU across breast, lung, and gastric cancers. The difference is that Daiichi’s ADCs showed overall survival benefits in randomized Phase 3 trials. ZYNLONTA has a 1.4-month PFS benefit and a toxicity signal in its confirmatory trial.

Risks

The first risk is the durability data. The 89.8% ORR and 77.6% CR in LOTIS-7 are as good as any DLBCL data reported, but if half of those complete responders relapse within 12 months, the combination is not commercially competitive with CAR-T. The full data in Q4 must show a median duration of response above 12 months and a 12-month CR rate above 50% to justify expanding the label.

The second risk is cash. $231 million sounds like a lot against a $134 million market cap, but ADC Therapeutics burned $33 million in Q1 alone. The company is spending roughly $120 to $130 million annually against $80 to $85 million in product revenue. The cash runway to early 2028 assumes no increase in spending. If LOTIS-7 data triggers a Phase 3 registrational trial, spending increases.

The third risk is the LOTIS-5 safety signal. A 13.2% Grade 5 TEAE rate is not an anomaly confined to one trial. The PBD dimer payload in ZYNLONTA is potent, and the toxicity profile will follow the drug into every combination. The FDA will not ignore a 2.9x higher fatal AE rate when reviewing any future sBLA. The LOTIS-7 safety data has shown a manageable profile so far, but the full data in 100 patients will either confirm or refute whether the glofitamab combination mitigates the toxicity. If serious infection rates climb with longer follow-up, the combination’s commercial potential shrinks regardless of the ORR.

Verdict

ADC Therapeutics has an approved drug, a promising combination with an 89.8% ORR, and $231 million in cash. The market is pricing all of that at $134 million. The market is not wrong, but it is too pessimistic by Q4.

The LOTIS-7 full data is the catalyst that matters. If durability holds at or above CAR-T benchmarks, ZYNLONTA plus glofitamab becomes a registrational asset, and ADCT re-rates from $134 million toward the $500 million to $1 billion range that a commercial-stage oncology company with a pipeline asset commands. If durability disappoints, ADCT is a $20 million-a-quarter product company burning $33 million a quarter, and $1.05 is the right price.

ADCT is not a buy ahead of the data. The LOTIS-5 safety signal and the uncertainty around LOTIS-7 durability make this a coin flip at best. But Q4 warrants close attention. A 12-month CR rate above 50% with a median DOR above 12 months would make ADCT the most undervalued oncology catalyst of 2026. Below those thresholds, the market’s current valuation is correct.

Source: ADC Therapeutics LOTIS-5 Phase 3 Results